Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) VP Kimberly Gentile Sells 5,000 Shares

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) VP Kimberly Gentile sold 5,000 shares of the stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $27.60, for a total value of $138,000.00. Following the completion of the sale, the vice president now owns 5,000 shares of the company’s stock, valued at $138,000. The sale was disclosed in a filing with the SEC, which is available at this link.

Kimberly Gentile also recently made the following trade(s):

  • On Friday, December 1st, Kimberly Gentile sold 5,000 shares of Biohaven Pharmaceutical stock. The shares were sold at an average price of $21.99, for a total value of $109,950.00.
  • On Wednesday, November 1st, Kimberly Gentile sold 5,000 shares of Biohaven Pharmaceutical stock. The shares were sold at an average price of $29.28, for a total value of $146,400.00.

Shares of Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) traded up $0.31 during trading on Friday, hitting $26.44. The stock had a trading volume of 195,387 shares, compared to its average volume of 402,781. The firm has a market capitalization of $1,100.00 and a P/E ratio of -5.07. Biohaven Pharmaceutical Holding Co Ltd has a 12 month low of $17.00 and a 12 month high of $39.51.

Several analysts recently issued reports on BHVN shares. Morgan Stanley reiterated an “overweight” rating and issued a $38.00 price target (down from $47.00) on shares of Biohaven Pharmaceutical in a report on Tuesday, October 3rd. Zacks Investment Research upgraded Biohaven Pharmaceutical from a “hold” rating to a “buy” rating and set a $25.00 target price for the company in a research note on Monday, December 4th. Piper Jaffray Companies set a $48.00 target price on Biohaven Pharmaceutical and gave the company a “buy” rating in a research note on Monday, December 11th. Needham & Company LLC lowered their target price on Biohaven Pharmaceutical from $43.00 to $36.00 and set a “buy” rating for the company in a research note on Tuesday, October 3rd. Finally, Canaccord Genuity began coverage on Biohaven Pharmaceutical in a research note on Friday, December 15th. They set a “buy” rating and a $30.00 target price for the company. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $36.14.

A number of large investors have recently bought and sold shares of BHVN. VHCP Management II LLC acquired a new position in Biohaven Pharmaceutical in the third quarter worth about $60,826,000. Eagle Asset Management Inc. acquired a new position in Biohaven Pharmaceutical in the third quarter worth about $32,635,000. Janus Henderson Group PLC acquired a new position in Biohaven Pharmaceutical in the third quarter worth about $25,751,000. JPMorgan Chase & Co. acquired a new position in Biohaven Pharmaceutical in the third quarter worth about $18,173,000. Finally, Stifel Financial Corp acquired a new position in Biohaven Pharmaceutical in the third quarter worth about $15,525,000. Institutional investors and hedge funds own 47.76% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) VP Kimberly Gentile Sells 5,000 Shares” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/01/13/biohaven-pharmaceutical-holding-co-ltd-bhvn-vp-sells-138000-00-in-stock.html.

Biohaven Pharmaceutical Company Profile

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Insider Buying and Selling by Quarter for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply